NEW YORK (GenomeWeb News) – Atossa Genetics reported on Tuesday that revenues in its third quarter dropped 27 percent year over year.

It also said it inked a new deal with Aspire Capital for the sale of up to $25 million in common stock during the next 30 months.

For the three months ended Sept. 30, Atossa posted $76,597 in revenues, down from $105,576 a year ago. Diagnostic testing service revenues slipped to $72,187 from $104,011, while product sales increased to $4,400 from $1,565.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.